Summary of findings ‐ ivacaftor vs placebo
QoL · adults and children with cystic fibrosis and with at least one R117H CFTR mutation
The review found no eligible studies for this question.
1 finding from 1 review
- Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis 2019 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found